Specializing in solving high-value / high-barrier, insolubility, bioavailability, and related drug product issues
Who we are
We are a privately held company in the Twin Cities (MN) area founded in 2001 through a technology license with University of Minnesota. Our initial technology focused towards medical devices and advanced nano-scale coating processes within a busines-to-business ‘technology services’ model.
We recently reorganized and restructured to scale-up technology, generate macro-particles for oral-solid drug development. We have demonstrated a strong proof-of-concept in enhancing low solubility drug performance and solid progress across our target drug pipeline. Our product enhancements span patient safety, convenience, compliance and effectiveness that have been achieved by overcoming challenging insolubility issues, increasing bio-availability performance and dramatically reducing defects.
Substantial investment from investors has made building a technically accomplished team and experienced industry management to create valuable 505(b)(2) opportunities a reality.
Mike has served as a member of Nanocopoeia’s board of directors since 2011. With more than 20 years of industry experience developing and commercializing numerous pharmaceutical drug products and creating significant business value, he continues to oversee that Nanocopoeia’s business value is maximized. Prior to Nanocopoeia, Mike was President and Chief Executive Officer of Paddock Laboratories, a developer, manufacturer and marketer of OTC and specialty brand and generic prescription products.
In less than three years, Mike grew sales from $65 million to over $220 million and successfully completed acquisition transaction to Perrigo for $540 million. Prior to Paddock Laboratories, Mike held multiple leadership positions including President, Par Pharmaceutical Generics Division (1998 – 2006). He has also held executive positions at two of the country’s largest pharmaceutical distributors. Mike is Chairman of the Board of Directors for Eagle Pharmaceuticals, and member of the board of directors of RiboCor, Inc.
Chief Operating Officer
Jim leads all day to day operations for Nanocopoeia’s business, technology and portfolio development. Jim brings more than 30 years of global Brand and generic manufacturing, product commercialization, engineering and operational excellence expertise. Prior to joining Nanocopoeia, Jim successfully led multiple business turnarounds serving in senior and executive leadership roles for companies such as; Teva Pharmaceuticals, Actavis/Watson, Perrigo, Paddock Labs, Par Pharmaceuticals, Andrx Pharmaceuticals, Pfizer and Parke-Davis.
Jim has been recognized for business leadership and innovative technical and operational contribution to some of the pharmaceutical industries largest global products and has established a successful track record of business performance, growth and profitability. Jim is a Summa Cum Laude graduate, Electrical Engineering, from Rochester Institute of Technology with a Masters in Technology Management from New Jersey Institute of Technology.
VP of Pharmaceutical Sciences
Dr. Wertz leads Nanocopoeia’s research and development efforts into novel pharmaceutical products. Chris has more than 20 years of industry experience, spanning all stages of product development across a wide range of product forms and platforms. Prior to joining Nanocopoeia, Chris was Director, Pharmaceutical Development at Upsher-Smith Laboratories, where he was responsible for formulation and process development in support of the company’s ANDA and NDA portfolios.
Chris also worked at Vertex and Elan Pharmaceuticals where he led their line extension and specialty formulation development. Dr. Wertz has M.S. and Ph.D. degrees in Chemical Engineering from Lehigh University and a B.S. degree in Chemical Engineering from the University of Minnesota.
Nanocopoeia is dedicated to providing a positive, team-oriented environment where colleagues may learn, grow and develop themselves. We welcome inquiries from all master’s or doctorate degree holders with medical, pharmaceutical, biotechnology, or chemistry backgrounds who recognize our vision, hold a positive attitude, and are committed to learning and teamwork. Please send your resume to email@example.com for more information.
Nanocopoeia has a solid history of successful partnering using both co-development and out-licensing business models. Our focus is to work collaboratively with our partners to build long-term value together. Please contact us if you would like to explore a potential partnership with us.